ClinicalTrials.gg
Status unknownNCT04705636COMPANION-CFUpdated Jan 22, 2021

Use of a Connected Companion in Children With Cystic Fibrosis

An interventional study of Connected device named "Leo" from Ludocare society in Cystic Fibrosis in Children and Chronic Disease, sponsored by Centre Hospitalier de Saint-Brieuc. Status unknown at 2 sites in France. Open to participants aged 3 Years to 11 Years. Per ClinicalTrials.gov, last updated 2021-01-22.

Sponsored by Centre Hospitalier de Saint-Brieuc · Not applicable, Interventional, and Supportive care

How we know

The sponsor has not verified this record recently (last verified Jan 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
3 Years to 11 Years
Sex
All
01

Study summary

The study will be conducted over a 6 months period. For the first three months, the child will be accompagned with a connected companion. After this period, the companion will be removed for three months in oder to prove this companion could improve treatment adherence for children suffering from cytolisis fibrosis.

This study will be conducted at the University Hospital Center of Rennes and Hospital Center of Saint-Brieuc.

Read the detailed description

In developed countries, chronic diseases with long-term therapy adherence is about 50%, according to the WHO report, and the adherence rate for regular intake of preventive therapies decreases to 28%.

For cystic fibrosis, rates are not much higher. Optimistic articles report an average compliance rate of 60%. Other articles report a rate of 50% which varies according to the age of the patient, the intake treatment complexity and burdensome drug treatment (physiotherapy achieves the lowest adherence with 38%), the disease understanding and the interest of treatment persuasion. Low adherence can also be the result of incorrect use of administration devices, for example for inhaled treatments. Technical errors are very frequent and affect around 30% of patients.

Families with children suffering from cystic fibrosis need daily support. Health professionals need to relay their recommendations at home. This is why new and funny tools dedicated to children with chronic illnesses are needed.

This trial will study the impact of connected companion named LEO® created by Ludocare company.

Study will be conducted as :

  • V0 : Companion given to the child
  • V1 : Companion removed after 3 months of use
  • V2 : Follow-up done between 1 and 3 months after the period without companion
02

Conditions studied

  • Cystic Fibrosis in Children
  • Chronic Disease

Browse trials for

Keywords

  • Connected device
  • Long-term therapy
  • Pneumology
  • Adherence therapy
  • Pediatric research
  • Pediatric device support
03

In context

Chronic Disease

782 studies on the registry are indexed under Chronic Disease; 144 are open to participants now.

This study's planned enrollment of 30 is below the median of 140 across 582 interventional studies indexed under Chronic Disease.

Browse Chronic Disease studies →

Lead sponsor

Centre Hospitalier de Saint-Brieuc is the lead sponsor of 9 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Child volunteer from 3 to 11 years old
  • Affected by cystic fibrosis
  • With a prescription containing at least two medications twice a day
  • Affiliation to the national health insurance
  • Child and holder of the exercise of parental authority understands and speaks French
  • The person exercising parental authority must have reached the age of majority.
  • Collection of the written consent of one of the holders of the exercise of parental authority

Exclusion criteria

Exclusion Criteria:

  • Non-voluntary child, under 3 years of age or over 12 years of age
  • Family reluctant to technology
  • Family without smartphone and/or wifi connection
  • Failure to obtain the written consent of one of the holders of the exercise of parental authority
  • Child involved in research involving the human person
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Connected device

    Connected device for three months period to support children care

    Device: Connected device named "Leo" from Ludocare society

Interventions

  • DeviceConnected device named "Leo" from Ludocare society

    Connected device named "Leo" from Ludocare society will be allocated to each child for three-months period. During this time, child will be helped to take all of his medication and specific care by this connected device.

06

What researchers measure

Primary outcomes

  1. Evaluate therapeutic adherence of children with cystic fibrosis aged 3 to 11 years with help of a connected medical companion

    The main evaluation criterion will be the overall compliance of the cohort in percentage terms. These data from connected companion will be refined for each type of treatment: pancreatic extracts, inhaled treatments, CFTR modulator, antibiotics, vitamins, laxative treatment, antacids, bile acids, food supplements, physiotherapy. For each treatment, the data "take" or "not take" will be treated by device and provide for statistical analysis in percentage. Each percentage will be grouped in global percentage will be therapeutic adherence all over study.

    Time frame: Through study completion, up to 6 months

Secondary outcomes

  1. Study of the reasons of low compliance or difficulties in taking the treatments

    Questionnaire for parents with up to 15 treatments which provide the major difficulties (to be indicated in order, from the most difficult to the simplest, with checked answers; no specific scale available)

    Time frame: At the inclusion

  2. Assess the psycho-social impact of treatment and illness

    Questionnaire for parents on child's behaviours in regard to taking treatment and illness (scale from 0 to 10, , highers scores mean better outcome)

    Time frame: At the inclusion

  3. Assess child's autonomy regarding his treatments

    Reporting in connected device

    Time frame: 3 months

  4. Assess the intake treatments quality

    Questionnaire for parents on difficulties frequency with checked answers (no specific scale available)

    Time frame: At the inclusion

  5. Evaluate any negative impacts associated with the use of the robot

    Questionnaire for parents on difficulties linked to the use of the robot with scale from 0 to 10, highers scores mean better outcome, and open ended questions (no specific scale is available)

    Time frame: 3 months

  6. Evaluate any negative impacts associated with the use of the robot

    Questionnaire for parents on difficulties linked to the use of the robot with scale from 0 to 10, highers scores mean better outcome, and open ended questions (no specific scale is available)

    Time frame: 4 to 6 months

  7. Assess the psycho-social impact of treatment and illness

    Questionnaire for children on his relation to his illness and his treatments (Color gradient scale with expressive smiley : red (sad), orange (a little bit sad), yellow (neutral), light green (good), dark green (very good)

    Time frame: at the inclusion

  8. Assess the psycho-social impact of treatment and illness

    Questionnaire for children on his relation to his illness and his treatments (Color gradient scale with expressive smiley : red (sad), orange (a little bit sad), yellow (neutral), light green (good), dark green(very good)

    Time frame: 3 months

  9. Assess the psycho-social impact of treatment and illness

    Questionnaire for children on his relation to his illness and his treatments (Color gradient scale with expressive smiley : red (sad), orange (a little bit sad), yellow (neutral), light green (good), dark green(very good)

    Time frame: 4 to 6 months

  10. Study of the reasons of low compliance or difficulties in taking the treatments

    Questionnaire for parents with up to 15 treatments which provide the major difficulties (to be indicated in order, from the most difficult to the simplest, with checked answers; no specific scale available)

    Time frame: 3 months

  11. Assess the psycho-social impact of treatment and illness

    Questionnaire for parents on child's behaviours in regard to taking treatment and illness (scale from 0 to 10, , highers scores mean better outcome)

    Time frame: 3 months

  12. Assess the intake treatments quality

    Questionnaire for parents on difficulties frequency with checked answers (no specific scale available)

    Time frame: 3 months

  13. Study of the reasons of low compliance or difficulties in taking the treatments

    Questionnaire for parents with up to 15 treatments which provide the major difficulties (to be indicated in order, from the most difficult to the simplest, with checked answers; no specific scale available)

    Time frame: 4 to 6 months

  14. Assess the psycho-social impact of treatment and illness

    Questionnaire for parents on child's behaviours in regard to taking treatment and illness (scale from 0 to 10, , highers scores mean better outcome)

    Time frame: 4 to 6 months

  15. Assess child's autonomy regarding his treatments

    Reporting in connected device

    Time frame: 4 to 6 months

  16. Assess the intake treatments quality

    Questionnaire for parents on difficulties frequency with checked answers (no specific scale available)

    Time frame: 4 to 6 months

07

Study locations

1 of 2 sites recruiting
  • Chu Rennes
    Rennes, 35000, France
    Not yet recruiting
    • Eric DENEUVILLE · Contact
  • Centre Hospitalier de Saint-Brieuc
    Saint-Brieuc, 22000, France
    Recruiting
    • Marie JAMIN · Contact
08

References and documents

Publications

  • De Geest S, Sabate E. Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs. 2003 Dec;2(4):323. doi: 10.1016/S1474-5151(03)00091-4. No abstract available. PubMed 14667488 ↗
  • Jentzsch NS, Camargos PAM, Colosimo EA, Bousquet J. Monitoring adherence to beclomethasone in asthmatic children and adolescents through four different methods. Allergy. 2009 Oct;64(10):1458-1462. doi: 10.1111/j.1398-9995.2009.02037.x. Epub 2009 Mar 28. PubMed 19416142 ↗
  • Zindani GN, Streetman DD, Streetman DS, Nasr SZ. Adherence to treatment in children and adolescent patients with cystic fibrosis. J Adolesc Health. 2006 Jan;38(1):13-7. doi: 10.1016/j.jadohealth.2004.09.013. PubMed 16387243 ↗
  • Conway SP, Pond MN, Hamnett T, Watson A. Compliance with treatment in adult patients with cystic fibrosis. Thorax. 1996 Jan;51(1):29-33. doi: 10.1136/thx.51.1.29. PubMed 8658364 ↗
  • Arias Llorente RP, Bousono Garcia C, Diaz Martin JJ. Treatment compliance in children and adults with cystic fibrosis. J Cyst Fibros. 2008 Sep;7(5):359-67. doi: 10.1016/j.jcf.2008.01.003. Epub 2008 Mar 4. PubMed 18304896 ↗
  • Sanchis J, Gich I, Pedersen S; Aerosol Drug Management Improvement Team (ADMIT). Systematic Review of Errors in Inhaler Use: Has Patient Technique Improved Over Time? Chest. 2016 Aug;150(2):394-406. doi: 10.1016/j.chest.2016.03.041. Epub 2016 Apr 7. PubMed 27060726 ↗
  • O'Donohoe R, Fullen BM. Adherence of subjects with cystic fibrosis to their home program: a systematic review. Respir Care. 2014 Nov;59(11):1731-46. doi: 10.4187/respcare.02990. Epub 2014 Jul 15. PubMed 25233386 ↗
  • Britto MT, Rohan JM, Dodds CM, Byczkowski TL. A Randomized Trial of User-Controlled Text Messaging to Improve Asthma Outcomes: A Pilot Study. Clin Pediatr (Phila). 2017 Dec;56(14):1336-1344. doi: 10.1177/0009922816684857. Epub 2017 Jan 5. PubMed 28056541 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Jun 2021, 5 months after the start.

Of 319 non-industry interventional studies with no phase under Chronic Disease, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 33. This study's planned 5 months is below that.

Counting every sponsor, half of 329 studies reached it within 21 months; a quarter within 11 and three quarters within 33.

Chronic Disease covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2020
First posted
Jan 12, 2021
StartActual
Jan 20, 2021
Primary completionEst.
Jun 2021
CompletionEst.
Jun 2021
Last update
Jan 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04705636
Lead sponsor
Centre Hospitalier de Saint-Brieuc
Responsible party
Sponsor
First posted
Jan 12, 2021
Start date
Jan 20, 2021
Primary completion
Jun 2021 (estimated)
Completion
Jun 2021 (estimated)
Last update
Jan 22, 2021

Study contacts

Marie JAMIN
Contact
marie.jamin@ch-stbrieuc.fr
+33296017818
Gwenaëlle LE GARFF
Contact
gwenaelle.legarff@armorsante.bzh
+33296017277
Marie JAMIN
principal investigator · Centre Hospitalier de Saint-Brieuc

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion